Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer

Completed · Phase 1

Conditions studied: HPV Associated Cancers

In brief

This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.

Key facts

Study ID

NCT05826275

Run by

Toragen, Inc.

People needed

28

Starts

2023-06-20

Expected to finish

2025-06-28

Last updated by the study team

2025-09-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Prior histologically confirmed HPV-associated squamous cell carcinoma, which is relapsed, resistant, or metastatic
• Life expectancy of at least 3 months
• Dose Escalation Phase: patients who have experienced disease progression on Standard of Care Therapies

You may not qualify if…

• Active CNS metastases
• Have any history of seizure disorder or are taking prophylactic seizure medication
• Have an active viral, bacterial, or fungal infection

Where it is running

• City of Hope — Duarte, California, United States
• UCSD Moores Cancer Center — La Jolla, California, United States
• Yale University — New Haven, Connecticut, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.